LU92509I2 - Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN) - Google Patents

Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN) Download PDF

Info

Publication number
LU92509I2
LU92509I2 LU92509C LU92509C LU92509I2 LU 92509 I2 LU92509 I2 LU 92509I2 LU 92509 C LU92509 C LU 92509C LU 92509 C LU92509 C LU 92509C LU 92509 I2 LU92509 I2 LU 92509I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
travatan
travoprost
acceptable derivatives
disclosed
Prior art date
Application number
LU92509C
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285486&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92509(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of LU92509I2 publication Critical patent/LU92509I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
LU92509C 1993-08-03 2014-07-25 Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN) LU92509I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/101,598 US5510383A (en) 1993-08-03 1993-08-03 Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension

Publications (1)

Publication Number Publication Date
LU92509I2 true LU92509I2 (fr) 2015-10-21

Family

ID=22285486

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92058C LU92058I2 (fr) 1993-08-03 2012-08-08 Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)
LU92509C LU92509I2 (fr) 1993-08-03 2014-07-25 Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92058C LU92058I2 (fr) 1993-08-03 2012-08-08 Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)

Country Status (13)

Country Link
US (3) US5510383A (fr)
EP (3) EP1920764B2 (fr)
JP (2) JP2791544B2 (fr)
AT (1) ATE286880T2 (fr)
AU (2) AU690120B2 (fr)
CA (1) CA2129287C (fr)
DE (1) DE69434228T2 (fr)
DK (3) DK1514548T3 (fr)
ES (3) ES2458493T3 (fr)
HK (2) HK1010717A1 (fr)
LU (2) LU92058I2 (fr)
PT (3) PT1514548E (fr)
SI (3) SI1920764T2 (fr)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
JP2001504100A (ja) * 1996-11-01 2001-03-27 アルコン・ラボラトリーズ・インコーポレーテッド 緑内障を治療するための炭酸脱水素酵素阻害剤とプロスタグランジンとの組合せの使用
US6649653B1 (en) 1996-11-12 2003-11-18 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
AU5436198A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
CN1269784A (zh) * 1997-09-09 2000-10-11 普罗克特和甘保尔公司 用作fp激活剂的芳香族c16－c20－取代四氢***素
NZ503735A (en) * 1997-09-09 2001-05-25 Procter & Gamble Aromatic C16-20-substituted tetrahydro prostaglandin F analogues useful as FP agonists
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
PL350917A1 (en) 1999-03-05 2003-02-10 Procter & Gamble C16 unsaturated fp-selective prostaglandins analogs
GB9908326D0 (en) * 1999-04-12 1999-06-09 Chirotech Technology Ltd Novel process intermediate for the synthesis of prostaglandins
US6294679B1 (en) * 1999-04-12 2001-09-25 Chirotech Technology Limited Intermediate for the synthesis of prostaglandins
US6214611B1 (en) 1999-04-12 2001-04-10 Chirotech Technology Limited Process for the preparation of prostaglandin precursors
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
AU2001228836A1 (en) * 2000-01-28 2001-08-07 Santen Pharmaceutical Co., Ltd. Novel difluoroprostaglandin derivative
AU3328601A (en) * 2000-02-01 2001-08-14 Cayman Chemical Co Inc Internal 1,15-lactones of fluprostenol and related prostaglandin F<sub>2alpha</sub> analogs and their use in the treatment of glaucoma and intraocular hypertension
US6660870B1 (en) 2000-03-17 2003-12-09 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2004098807A1 (fr) * 2000-11-21 2004-11-18 Barsplice Products, Inc. Procede de fabrication de coupleurs en acier permettant d'assembler des barres d'armature du beton
SE0100158D0 (sv) * 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US20050171054A1 (en) * 2001-01-19 2005-08-04 Helge Rask-Andersen Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss
EP1418903A2 (fr) * 2001-04-23 2004-05-19 The Board of Regents of the University of Texas System Prostanoides pouvant augmenter la penetration de medicaments oculaires
US20030212107A1 (en) * 2001-05-10 2003-11-13 Kapin Michael A. R-reliprodil for treating glaucoma
GB0112699D0 (en) 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
JP2004534781A (ja) * 2001-06-01 2004-11-18 アルコン，インコーポレイテッド 新規なアリールアミノプロパン類似体および緑内障治療へのこれらの使用
WO2002098860A1 (fr) * 2001-06-01 2002-12-12 Alcon, Inc. Indazoles et indoles nouveaux fusionnes et leur utilisation dans le traitement de glaucomes
BR0210241A (pt) * 2001-06-01 2004-08-10 Alcon Inc Piranoindazóis e seu uso no tratamento de glaucoma
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
AU2003222049B2 (en) * 2002-03-21 2007-05-31 Cayman Chemical Company, Incorporated Prostaglandin F2 alpha analogs in combination with antimicrobials for treating glaucoma
DE60334905D1 (de) 2002-06-06 2010-12-23 Merck Frosst Canada Ltd 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
EP1513523A1 (fr) * 2002-06-06 2005-03-16 Merck Frosst Canada &amp; Co. DERIVES D IMIDAZOLIDINE-2-ONE DISUBSTITUES EN 1,5 UTILES EN TANT QU AGONISTES DU RECEPTEUR EP sb 4 /sb DANS LE TRAITEME NT DE TROUBLES OCULAIRES ET DE MALADIES OSSEUSES
US6864282B2 (en) * 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
CA2495917A1 (fr) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
CN100425241C (zh) * 2002-08-29 2008-10-15 参天制药株式会社 由Rho激酶抑制剂和***素类物质构成的青光眼治疗剂
CN1678302A (zh) * 2002-08-30 2005-10-05 爱尔康公司 取代的5－苯并二氢吡喃－5－基－乙胺化合物及其在治疗青光眼中的用途
US20060167081A1 (en) * 2002-10-25 2006-07-27 Xavier Billot Ep4 receptor agonists
US7528163B2 (en) * 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
CA2504226A1 (fr) * 2002-11-12 2004-05-27 Alcon, Inc. Inhibiteurs d'histone deacetylase destines au traitement de maladies degeneratives de l'oeil
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
KR101103141B1 (ko) 2002-11-18 2012-01-04 산텐 세이야꾸 가부시키가이샤 Ｒｈｏ 키나아제 억제제와 β 차단약으로 이루어진 녹내장치료제
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
EP1581209A4 (fr) * 2002-12-13 2009-03-11 Alcon Inc Nouveaux analogues de benzopyranne et leur utilisation pour le traitement du glaucome
AR043161A1 (es) * 2003-02-14 2005-07-20 Sucampo Pharmaceuticals Inc Composicion oftalmica para tratar hipertension ocular y glaucoma
JP2007521296A (ja) * 2003-07-01 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧の治療のための眼科用組成物
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
CN1845914A (zh) * 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
WO2005025568A1 (fr) * 2003-09-04 2005-03-24 Merck & Co., Inc. Compositions ophtalmiques pour traiter l'hypertension oculaire
ATE425971T1 (de) * 2003-09-04 2009-04-15 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
MXPA06002484A (es) * 2003-09-05 2006-06-20 Novartis Ag Composiciones que comprenden derivados de benzo[g]quinolina y derivados de prostaglandina.
ES2331313T3 (es) 2003-11-07 2009-12-29 Senju Pharmaceutical Co., Ltd. Composicion farmaceutica que contiene prostaglandina.
WO2005053688A1 (fr) * 2003-11-26 2005-06-16 Alcon, Inc. Furo[2,3-g] indazoles substitues destines au traitement du glaucome
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (fr) * 2003-12-15 2005-06-30 Alcon, Inc. [1,4]oxazino[2,3-g]indazoles substitues pour traiter le glaucome
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
WO2005079809A1 (fr) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. Gouttes pour les yeux transparentes au latanoprost
CN1946384B (zh) * 2004-04-26 2011-04-20 爱尔康公司 治疗眼高压和青光眼的他汀类
WO2006020003A2 (fr) 2004-07-20 2006-02-23 Merck & Co., Inc. Compositions ophtalmiques traitant l'hypertension oculaire
EP1802299A2 (fr) * 2004-10-13 2007-07-04 Merck & Co., Inc. Compositions ophtalmiques de traitement de l'hypertension oculaire
CA2583593A1 (fr) * 2004-10-13 2006-04-27 Merck & Co., Inc. Compositions ophtalmiques servant a traiter l'hypertension oculaire
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US7425572B2 (en) * 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
DE602006013945D1 (de) * 2005-01-14 2010-06-10 Allergan Inc Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (fr) 2009-03-04 2010-09-10 Allergan, Inc. Solution ophtalmique améliorée à base de bimatoprost
US20090234005A1 (en) 2005-03-31 2009-09-17 Naruhiro Ishida Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient
CN101160128B (zh) 2005-04-13 2010-08-18 宇部兴产株式会社 含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
WO2007002670A2 (fr) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Procede pour faire baisser la pression intraoculaire
AU2006275263A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
EP1810967B1 (fr) 2006-01-18 2014-07-30 Chirogate International Inc. Procédé et produits intérmediaires pour la fabrication de prostaglandines
EP1986666A1 (fr) * 2006-02-06 2008-11-05 Synphora AB Nouvelles méthode et compositions pour traiter un acouphène
WO2007105691A1 (fr) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. Composition aqueuse
US20090062280A1 (en) * 2006-03-13 2009-03-05 Doherty James B Ophthalmic Compositions for Treating Ocular Hypertension
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
WO2007146136A2 (fr) * 2006-06-12 2007-12-21 Merck & Co., Inc. Compositions ophtalmiques pour traiter une hypertension oculaire
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
JP5313125B2 (ja) 2007-02-28 2013-10-09 旭化成ファーマ株式会社 スルホンアミド誘導体
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
EP2291346A2 (fr) * 2008-05-15 2011-03-09 Allergan, Inc. Cyclopentanes substitués à visée thérapeutique
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
AU2009340420A1 (en) 2008-10-29 2010-08-26 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2010112615A1 (fr) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Dérivés de lysine fonctionnalisés avec des lipides
CA2929545C (fr) 2009-05-01 2019-04-09 Aerie Pharmaceuticals, Inc. Inhibiteurs a mecanisme double pour le traitement de maladie
US20120184552A1 (en) 2009-09-17 2012-07-19 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
KR101769637B1 (ko) * 2009-11-09 2017-08-18 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
EP2389939A1 (fr) 2010-05-28 2011-11-30 Novagali Pharma S.A. Utilisation de prostaglandines F2alpha et analogues pour la cicatrisation des lésions de la cornée et du conjonctif
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
WO2012018324A1 (fr) 2010-08-02 2012-02-09 Athena Cosmetics, Inc. Composition, procédé et kit pour améliorer l'apparence des cheveux
BR112013014021A8 (pt) 2010-12-06 2017-10-03 Follica Inc Métodos para tratamento de calvície e promoção de crescimento de cabelos
EP3378480A1 (fr) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Procédés et compositions de traitement du syndrome métabolique
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CN105902551A (zh) 2011-02-04 2016-08-31 兴和株式会社 用于预防或治疗青光眼的药物疗法
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
HU231203B1 (hu) 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
US20150031898A1 (en) * 2012-03-09 2015-01-29 Instytut Farmaceutyczny Process for preparation of prostaglandin f2 alpha analogues
KR101651448B1 (ko) 2012-11-21 2016-08-26 토포카인 쎄라퓨틱스, 인코포레이티드 체지방을 국소적으로 증가시키는 방법 및 조성물
HU230744B1 (hu) 2012-11-30 2018-01-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
HUE061618T2 (hu) 2013-03-15 2023-07-28 Aerie Pharmaceuticals Inc Vegyület szemrendellenességek kezelésére
NO2753788T3 (fr) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
JP2017502089A (ja) 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置
HU231214B1 (hu) 2014-03-13 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás nagytisztaságú prosztaglandinok előállítására
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
CA2964364A1 (fr) * 2014-10-15 2016-04-21 Novartis Ag Conjugues et derives de prostaglandine pour traitement du glaucome et de l'hypertension oculaire
US11285163B2 (en) 2014-10-20 2022-03-29 Sentiss Pharma Private Limited Ophthalmic solution
EP3223793B1 (fr) 2014-11-25 2023-06-28 Eximore Ltd. Compositions et procédés d'administration d'un agent bio-actif ou d'agents bio-actifs
US10280138B2 (en) 2015-03-31 2019-05-07 Nicox S.A. Nitric oxide donating derivatives of fluprostenol
EP3355799B1 (fr) 2015-09-27 2021-09-01 Follica, Inc. Dispositif de piqûre et applicateur de médicament
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
DE102016110381A1 (de) * 2016-06-06 2017-12-07 Edwin Kohl Kosmetische Zusammensetzung, insbesondere zur Förderung des Haarwuchses
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
CA3035566A1 (fr) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Compositions ophtalmiques
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
GB1350971A (en) * 1971-05-11 1974-04-24 Imp Chemi Als Ind Ltd Cyclopentane derivatives
GB1451798A (en) * 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
GB1486832A (en) * 1974-08-05 1977-09-28 Ici Ltd Prostanoic acid derivatives
DE2523676A1 (de) * 1975-05-26 1976-12-16 Schering Ag Neue prostanderivate und verfahren zu ihrer herstellung
US4159343A (en) * 1975-05-26 1979-06-26 Schering Aktiengesellschaft Prostane derivatives
NL7605381A (nl) * 1975-05-26 1976-11-30 Schering Ag Werkwijze voor het bereiden van prostaanderi- vaten en werkwijze voor het bereiden van een geneesmiddel met prostaglandinewerking.
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
ATE82499T1 (de) * 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
WO1990002553A1 (fr) * 1988-09-06 1990-03-22 Pharmacia Ab Derives de prostaglandine servant au traitement des glaucomes ou de l'hypertension oculaire
ATE111736T1 (de) * 1988-10-01 1994-10-15 R Tech Ueno Ltd Okulare hypotensive mittel.
CA2031469A1 (fr) * 1989-12-28 1991-06-29 Larry A. Wheeler Utilisation de composes d'inclusion de prostaglandines avec des cyclodextrines dans le traitement de l'hypertension oculaire
HU212570B (en) † 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
DE69311361T2 (de) * 1992-10-13 1998-01-08 Alcon Lab Inc Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
EP1920764B1 (fr) 2012-05-16
ES2385267T5 (es) 2020-07-21
AU7748898A (en) 1998-10-01
SI1920764T1 (sl) 2012-08-31
ES2458493T3 (es) 2014-05-05
PT1514548E (pt) 2014-04-22
ES2458493T8 (es) 2014-08-27
EP1514548A3 (fr) 2005-04-06
LU92058I2 (fr) 2012-10-08
CA2129287A1 (fr) 1995-02-04
EP1514548B1 (fr) 2014-02-26
EP0639563B2 (fr) 2015-09-30
EP0639563A2 (fr) 1995-02-22
SI1514548T1 (sl) 2014-04-30
US5889052A (en) 1999-03-30
DE69434228T2 (de) 2006-02-02
DK1514548T3 (da) 2014-03-17
CA2129287C (fr) 2002-05-14
ATE286880T2 (de) 2005-01-15
EP1920764B2 (fr) 2020-01-08
AU690120B2 (en) 1998-04-23
DK1920764T4 (da) 2020-03-16
JP2791544B2 (ja) 1998-08-27
HK1010717A1 (en) 1999-06-25
SI1920764T2 (sl) 2020-03-31
JP3650258B2 (ja) 2005-05-18
HK1072716A1 (en) 2005-09-09
DK1920764T3 (da) 2012-07-02
EP1920764A1 (fr) 2008-05-14
DK0639563T4 (en) 2016-01-11
US5665773A (en) 1997-09-09
EP0639563A3 (fr) 1996-10-16
AU704670B2 (en) 1999-04-29
US5510383A (en) 1996-04-23
SI0639563T1 (en) 2005-06-30
ES2235158T5 (es) 2016-05-25
PT639563E (pt) 2005-05-31
ES2235158T3 (es) 2005-07-01
ES2385267T3 (es) 2012-07-20
DK0639563T3 (da) 2005-03-21
JPH10182465A (ja) 1998-07-07
PT1920764E (pt) 2012-07-20
EP0639563B1 (fr) 2005-01-12
DE69434228D1 (de) 2005-02-17
EP1514548A2 (fr) 2005-03-16
AU6877994A (en) 1995-02-23
JPH07165703A (ja) 1995-06-27

Similar Documents

Publication Publication Date Title
LU92509I2 (fr) Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)
LU91541I2 (fr) latanoprost et ses dérivés pharmaceutiquement acceptables (XALATAN)
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
NO973122D0 (no) Middel for å minske okular spenning
EP1142576A4 (fr) Compositions de medicament pour traiter l&#39;hypertension oculaire ou le glaucome
NO20020475D0 (no) 2-aminotetralinderivater for terapi av glaukom
EP1300150A3 (fr) Dérivés de prostaglandines servant au traitement du glaucome ou de l&#39;hypertension oculaire